Olof Nord - Biotage AB Exec Devel
| BIOT Stock | SEK 155.00 3.90 2.58% |
Insider
Olof Nord is Exec Devel of Biotage AB
| Age | 48 |
| Phone | 46 18 56 59 00 |
| Web | https://www.biotage.com |
Biotage AB Management Efficiency
The company has return on total asset (ROA) of 0.109 % which means that it generated a profit of $0.109 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1785 %, meaning that it generated $0.1785 on every $100 dollars invested by stockholders. Biotage AB's management efficiency ratios could be used to measure how well Biotage AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | INSIDER Age | ||
| Peter Mah | Anoto Group AB | N/A | |
| Fredrik Jarrsten | Orexo AB | 56 | |
| MD MBA | Orexo AB | N/A | |
| Edward Belgeonne | Anoto Group AB | 61 | |
| Nuno Allen | Anoto Group AB | 46 | |
| Seunghoon Song | Anoto Group AB | N/A | |
| Dennis Urbaniak | Orexo AB | 54 | |
| Long Phan | Anoto Group AB | N/A | |
| Johannes Haglund | Anoto Group AB | N/A | |
Management Performance
| Return On Equity | 0.18 | |||
| Return On Asset | 0.11 |
Biotage AB Leadership Team
Elected by the shareholders, the Biotage AB's board of directors comprises two types of representatives: Biotage AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotage. The board's role is to monitor Biotage AB's management team and ensure that shareholders' interests are well served. Biotage AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotage AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tomas Blomquist, CEO Pres | ||
| Raffaella Bombarda, EVP Marketing | ||
| Maja Nilsson, Chief Officer | ||
| CS BSc, Ex Operations | ||
| JonSverre Schanche, Chief Officer | ||
| Olof Nord, Exec Devel | ||
| Lars LLB, Chief Officer | ||
| Petra Duprez, Chief Officer | ||
| Jonas Stahlberg, Chief Auditor | ||
| Scott Carr, Pres Americas |
Biotage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biotage AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.16 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 12.84 B | |||
| Shares Outstanding | 65.98 M | |||
| Shares Owned By Insiders | 0.58 % | |||
| Shares Owned By Institutions | 64.57 % | |||
| Price To Earning | 38.27 X | |||
| Price To Book | 8.12 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Biotage Stock Analysis
When running Biotage AB's price analysis, check to measure Biotage AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotage AB is operating at the current time. Most of Biotage AB's value examination focuses on studying past and present price action to predict the probability of Biotage AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotage AB's price. Additionally, you may evaluate how the addition of Biotage AB to your portfolios can decrease your overall portfolio volatility.